American Well Corporation v. Indegene Limited

District Court, D. New Jersey·Decided December 19, 2025·No. 3:25-cv-01318·Unknown

Opinion

NOT FOR PUBLICATION

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

AMERICAN WELL CORPORATION,

Plaintiff, Civil Action No. 25-1318 (ZNQ) (JTQ)

v. OPINION

INDEGENE LIMITED,

Defendant.

QURAISHI, District Judge THIS MATTER comes before the Court upon a Motion to Dismiss filed by Defendant Indegene Limited (“Defendant” or “Indegene”). (ECF No. 11.) Defendant filed a memorandum of law in support of its Motion. (“Moving Br.,” ECF No. 11-1.) Plaintiff American Well Corporation (“Plaintiff” or “Amwell”) filed an Opposition (ECF No. 17), to which Defendant replied (ECF No. 18). The Court has carefully considered the parties’ submissions and decides the Motion without oral argument pursuant to Federal Rule of Civil Procedure 78 and Local Civil Rule 78.1. For the reasons set forth below, the Court will GRANT Defendant’s Motion. I. BACKGROUND AND PROCEDURAL HISTORY This action arises out of a contract dispute between Amwell and Indegene. Under a partner agreement between the parties (the “Partner Agreement”), Defendant was authorized to license and sell Plaintiff’s software to third-party customers. (“Compl.,” ECF No. 1 ¶ 26.) As will be explained in more detail below, the dispute centers on whether the Partner Agreement requires Defendant to pay a Subscription Fee to Plaintiff even though Defendant did not license or sell Plaintiff’s software to any third-party customers. As alleged, Plaintiff develops and maintains software application platforms for the provision of telehealth services. (Id. ¶ 2.) One of Plaintiff’s subsidiaries, Conversa Health LLC

(“Conversa”), has proprietary software “that enables individual end users to engage in automated digital conversations about their health, health education, and related matters.” (Id. ¶ 27.) Defendant offers research, development, and management services to healthcare and pharmaceutical companies. (Id. ¶ 7.) On December 23, 2021, Plaintiff and Defendant entered into the Partner Agreement. (Id. ¶ 17.) Pursuant to Section 2.1 of the Partner Agreement, Defendant was granted a “non-exclusive, non-transferable license and right to use, market, resell and distribute the Conversa Services in the [United States].” (Partner Agreement (DX B) § 2.1; see also Compl. ¶ 26.)1 “Conversa Services” is defined in the Partner Agreement as: (a) the hosting, management, and operation of Conversa’s proprietary Software-as-a-Service (“SaaS”) that enables Conversa to provide Customer with automated, interactive digital conversation services (or “chat” sessions) with End Users, including all know-how, devices, methods, processes, other technologies and inventions, technical or functional descriptions, requirements, documentation, instructions, deliverables, user design appearance, content used in chat sessions, and content and functionality of Customer dashboards and related items used by Conversa to provide such Services; (b) related services provided by Conversa to Customer, as described in the applicable Service Order; and (c) any optional Implementation Services provided by Conversa to Customer pursuant to an applicable Service Order.

1 References to “DX” refer to the Exhibits accompanying Defendant’s Declaration of Cameron A. Smith at ECF Nos. 11-2–6 and attached to Defendant’s Motion to Dismiss. References to “PX” refer to the Exhibits attached to Plaintiff’s Complaint at ECF Nos. 1-1–4. (Compl. ¶ 27; see also Partner Agreement (DX B) § 1.4.) Plaintiff and Defendant also executed Service Order #1 the same day as the Partner Agreement. (Id. ¶ 31.) According to Plaintiff, the Service Order “concerned the configuration and development by Amwell and Indegene Limited of a program with a focus on medication adherence

for Indegene Limited’s customers.” (Id. ¶ 34.) The development and implementation of this program was projected in the Statement of Work attached to the Service Order. (Id. ¶ 36.) The term of the Service Order was for 12 months and had an annual subscription fee of $250,000. (Id. ¶ 38.) The annual fee was divided into two payments, with 50% of the annual fee payable on March 1, 2022, and the remaining 50% payable on July 1, 2022. (Id. ¶ 39.) Consistent with the Service Order, Plaintiff issued its first invoice to Defendant on March 1, 2022 for $125,000. (Id.¶ 48.) On July 1, 2022, Plaintiff issued its second invoice to Defendant for the remaining $125,000. (Id. ¶ 50.) According to Plaintiff, Defendant “has failed to timely pay the monies owed to Amwell under the Partner Agreement and Service Order . . . and efforts by Amwell to collect payment from Indegene Limited have been ignored, rejected, or otherwise

Free access — add to your briefcase to read the full text and ask questions with AI

American Well Corporation v. Indegene Limited, (D.N.J. 2025).

American Well Corporation v. Indegene Limited (American Well Corporation v. Indegene Limited) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related